Novartis International AG was founded in 1996, and is a very popular brand name in pharma.
Image: company logo
It was a result of the merger of two companies - Ciba-Geigy and Sandoz Laboratories, where Ciba-Geigy was formed by the merger of CIBA and J R Geigy Ltd. The company is headquartered in Basel, Switzerland and Joseph Jimenez serves as the CEO of the company while Joerg Reinhardt is the chairman of Novartis.
As of 2015, the company has an employee strength of 118,700. Novartis products are available in more than 180 countries.
Its count of patents is 972 million. Novartis did acquisition of GlaxoSmithKline’s (GSK) oncology products. The leading divisions of the company are Pharmaceuticals, Alcon and Sandoz. Alcon provides eye products while Sandoz is active in growing generic medicines industry. The Alcon division had disappointing performance which was offset by the strong performance of the company's Pharmaceuticals and Sandoz Divisions. Novartis is targeting growing areas of healthcare to develop innovative products.
The company had a revenue of $ 49440 million in 2015. Its total profits were $ 17794 million. The market capitalization of the company was at $ 210960 million. The innovations at Novartis happens in Novartis Institutes for BioMedical Research. This institute has more 6000 scientists and physicians. Company has unique program Novartis Access. This program is designed for low and middle income countries. It helps the countries to fight against deaths from chronic diseases.